FDA.reportPublic FDA data

VILANTEROL Pharmacologic Class Indexing

Class set ID
f15ebd9f-ef32-44a0-9641-3f1ed4f92f4a
Version
2
Effective date
20180813
Type
Indexing - Pharmacologic Class

Mapped DailyMed Labels#

Label, Manufacturer, Effective table
LabelManufacturerEffectiveSPL version
These highlights do not include all the information needed to use Umeclidinium and Vilanterol ELLIPTA safely and effectively. See full prescribing information for Umeclidinium and Vilanterol ELLIPTA. Umeclidinium and Vilanterol ELLIPTA inhalation powder, for oral inhalation use Initial U.S. Approval: 2013Prasco Laboratories | GlaxoSmithKline LLC202411223
These highlights do not include all the information needed to use Fluticasone Furoate/Vilanterol ELLIPTA safely and effectively. See full prescribing information for Fluticasone Furoate/Vilanterol ELLIPTA. Fluticasone Furoate/Vilanterol ELLIPTA inhalation powder, for oral inhalation use Initial U.S. Approval: 2013Prasco Laboratories | GlaxoSmithKline LLC202411216
These highlights do not include all the information needed to use BREO ELLIPTA safely and effectively. See full prescribing information for BREO ELLIPTA. BREO ELLIPTA (fluticasone furoate and vilanterol inhalation powder), for oral inhalation use Initial U.S. Approval: 2013GlaxoSmithKline LLC2024110728
These highlights do not include all the information needed to use ANORO ELLIPTA safely and effectively. See full prescribing information for ANORO ELLIPTA. ANORO ELLIPTA (umeclidinium and vilanterol inhalation powder), for oral inhalation use Initial U.S. Approval: 2013GlaxoSmithKline LLC2023060229
These highlights do not include all the information needed to use TRELEGY ELLIPTA safely and effectively. See full prescribing information for TRELEGY ELLIPTA. TRELEGY ELLIPTA (fluticasone furoate, umeclidinium, and vilanterol inhalation powder), for oral inhalation use Initial U.S. Approval: 2017GlaxoSmithKline LLC2023060214